The Effectiveness of The Use of Antihyperuricemia Against Decrease In Uric Acid Levels In Hypertensive Patients With Gout at Puskesmas X Rembang Regency
DOI:
https://doi.org/10.51601/ijhp.v6i3.694Abstract
This study aims to evaluate the effectiveness of the use of antihyperuricemic drugs in reducing uric acid levels in hypertensive patients who also suffer from gout at Community Health Center 1 Rembang. This type of research is a quantitative study with a cross-sectional design, using secondary data from medical records from 2024–2025. In this study, there were 91 respondents who met the inclusion criteria. The dominant characteristic of the respondents was men aged 51–65 years with an educational background ranging from elementary to junior high school. The most commonly used antihypertensive drug was amlodipine (85.7%). Before undergoing therapy, all patients (100%) showed abnormal blood pressure levels. After antihypertensive therapy, 45 patients (49.5%) had normal blood pressure, while 46 patients (50.5%) were in the abnormal category with amlodipine in 78 patients (85.7%) and captopril in 11 patients (12.1%), while the most common antihyperuricemic drug was allopurinol (87.9%). Before undergoing therapy, all patients (100%) showed abnormal uric acid levels. After antihyperuricemic therapy, 23 patients (25.3%) managed to achieve normal uric acid levels, while 68 patients (74.7%) remained in the abnormal category. Bivariate analysis showed that the average uric acid level before therapy was 8.9 mg/dL, which decreased to 7.3 mg/dL after therapy, with an average decrease reaching 1.6 mg/dL. Paired t-test indicated a p value = 0.000 (p < 0.05), indicating a significant difference between the conditions before and after therapy. In conclusion, the application of antihyperuricemia has been proven effective in reducing uric acid levels in patients with hypertension who also have gout at Community Health Center 1 Rembang.
Downloads
References
[1] Agustina, R., and others. (2024). Comparison of antihypertensive therapy outcomes in primary care patients. Indonesian Journal of Clinical Pharmacy.
[2] Alghubayshi, A., Edelman, A., Alrajeh, K., & Roman, Y. (2022). Genetic assessment of hyperuricemia and gout in Asian, Native Hawaiian, and Pacific Islander subgroups of pregnant women : biospecimens repository cross - sectional study. BMC Rheumatology, 1–13. https://doi.org/10.1186/s41927-021-00239-7
[3] Amal, N., & others. (2025). Effectiveness comparison of captopril 25 mg and amlodipine 5 mg in reducing blood pressure among hypertensive patients. International Journal of Health Practice.
[4] Anggraini, D. (2022). Clinical Aspects of Hyperuricemia. Clinical Aspects of Debie's Hyperuricemia, Vol I No 4, 1–10.
[5] Crisantika, E., Sintia, N., & Wahyuni, C. U. (2024). The Relationship between Purine Consumption and Hypertension on Repeated Attacks of Gout Attrition in Patients at the Krembangan District Health Center in 2022. Health Nutrition Media, 13(1), 214–219. https://doi.org/10.20473/mgk.v13i1.2024.214-219
[6] Health Office. (2023). Health Profile of Kudus Regency in 2023. Kudus Regency Health Office, 15.
Eliza, Muzakar, & Nazarena, Y. (2022). Provision of soursop juice (Annona muricata linn) and nutrition education for hyperuricemia patients. 6(3), 2096–2103.
[7] FitzGerald, J. D., Dalbeth, N., Mikuls, T., & others. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6), 744–760. https://doi.org/10.1002/acr.24180
[8] Fitzgerald, M., & others. (2020). Hypothermia, coagulopathy, and trauma-induced coagulopathy: Mechanisms and clinical implications. Journal of Trauma and Acute Care Surgery, 89(2), 303–310.
[9] Girigoswami, K., Arunkumar, R., & Girigoswami, A. (2024). Annals of Medicine Management of hypertension addressing hyperuriceemia : introduction of nano-based approaches. Annals of Medicine, 56(1). https://doi.org/10.1080/07853890.2024.2352022
[10] Hadad, M. G. I., Manaf, A. A., & The, F. (2024). Characteristics of Gout Arthritis Patients at Dr. H. Chasan Boesoirie Ternate Regional General Hospital. Cerdika: Indonesian Scientific Journal, 4(10), 875–883. https://doi.org/10.59141/cerdika.v4i8.855
[11] Herman, H., Sukmawati, & Pranada Andi Desiah. (2021). Comparison Of Efficacy And Safety Of The Use Of Febuxostat And Allopurinol In Gout Patients. Journal Of Pharmacy, 1(13), 55–56.
[12] Hotea, I., Pop-Moldovan, V., Pamfil, C., & Rednic, S. (2023). Real-life results of urate-driven pharmacotherapy with three urate lowering drugs in gout: allopurinol, febuxostat and benzbromarone. Exploration of Musculoskeletal Diseases, 1(4), 233–245. https://doi.org/10.37349/emd.2023.00071
[13] Science, B. (2023). Research Ethics Clearance What is Research Ethics Clearance?
Juraschek, S. P., & others. (2020). The Effects of Antihypertensive Class on Gout in Older Adults: Secondary Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Hypertension. https://doi.org/10.1097/HJH.0000000000002359
[14] Khusna, A. D. A., Zakiudin, A., & Janah, E. N. (2025). Nursing Care For Families With Musculoskeletal System Disorders: Arthritic Gout In Ny. M In Dk. Petenteng Rt 02 Rw 04 Purwodadi Village, Tonjong District, Brebes Regency. Health Sciences, 21(1), 1–10. https://doi.org/10.5455/mnj.v1i2.644
[15] Kragh, N., Worsfold, A., Oladapo, A., & others. (2025). Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States. Advances in Therapy. https://doi.org/10.1007/s12325-025-03189-5
[16] Kreutz, R., Brunstr"om, M., Burnier, M., & others. (2024). 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. European Journal of Internal Medicine, 126, 1–15. https://doi.org/10.1016/j.ejim.2024.05.033
[17] Lukitaningtyas, D., & Cahyono, E. A. (2023). Hypertension; Article Review. Development Of Health Sciences And Practices, 2 (April), 100–117.
[18] Marfianti, E., Fitriyati, Y., Febriani, T. B., Suharni, A., Widayati, S., Afievudin, A., & Mujiyanto, M. (2024). Screening and Education of Hyperuricemia in Pre-Elderly and Elderly in Besi Sukoharjo Hamlet, Sleman, Yogyakarta. Journal of Community Service Medika, 4(1). https://doi.org/10.23917/jpmmedika.v4i1.2192
[19] McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canu, M. H., Ceconi, C., Chazova, I., Custodis, ., & et al. (2024). 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal, 45(38), 3912–4018. https://doi.org/10.1093/eurheartj/ehae178
[20] NICE. (2022). Gout: diagnosis and management (Issue NG219).
[21] Pasaeno, N. A., Ridwan, B. A., & Useng, Y. (2025). Hubungan Rasionalitas Penggunaan Obat Antidiabetes Dengan Kadar Glukosa Darah Sewaktu Pasien Rawat Jalan Diabetes Melitus Tipe II di UPTD Puskesmas Laosu The Relationship between the Rationality of Using Antidiabetic Drugs and Blood Glucose Levels When Ou. 4(4).
[22] PDHI. (2022). InaSH Virtual Scientific Meeting February 19–20, 2022: Proceedings Book.
[23] PERHI. (2021). Hypertension Management 2021: PERHI Consensus Update 2019 Hypertension Management 2021: PERHI 2019 Consensus Update.
[24] Polónia, J., Mesquita Bastos, J., & colleagues. (2024). Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study. Blood Pressure, 33(1), 2377157. https://doi.org/10.1080/08037051.2024.2377157
[25] Prabhakar, D., Jeemon, P., Joshi, S. R., Chaturvedi, A., Badiger, S., Singh, R., & others. (2023). Effectiveness of Amlodipine in the Control of 24-Hour Blood Pressure in Mild-to-Moderate Essential Hypertension: A Prospective, Multicenter, Observational Real-World Study from India. Cureus, 15(4), e38249. https://doi.org/10.7759/cureus.38249
[26] Rheumatology. (2024a). Guidelines for the Diagnosis and Management of Hyperuricemia & Gout Arthritis. Indonesian Rheumatology Association.
[27] Rheumatology, P. (2024b). Guidelines for Diagnosis and Administration.
[28] R. J., I., Pailan, E. T., & Baharuddin, B. (2023). Risk Factor Analysis of Gout Arthritis. Sandi Husada Health Scientific Journal, 12(1), 157–162. https://doi.org/10.35816/jiskh.v12i1.919
[29] Rosnarita, I. A., Khudzaifi, M., & Priswa, N. (2025). Evaluation of the Safety of Oral NSAID Treatment on Blood Pressure in Osteoarthritis Patients: A Cardiovascular Event Prevention Study. 21(1), 30–36.
[30] Saifudin Zukhri, & Devi Permatasari. (2022). The Relationship between Diet and Activity Patterns and the Control of Gout Levels in Hyperuricemia Patients. TRIAGE Journal of Nursing Sciences, 9(2), 1–5. https://doi.org/10.61902/triage.v9i2.598
[31] Septiani, V., Suherman, L. P., Susiani, S., Rukmawati, I., & Wahyuni, E. (2023). Identification of Drug-Related Problems in Comorbid Arthritis Hypertension Patients at One of the Health Centers in the City of Bandung. Scientific Journal of Marine Farming, 14(1). https://doi.org/10.52434/jfb.v14i1.1943
[32] Shin, A., Choi, S. R., Han, M., Ha, Y. J., Lee, Y. J., Lee, E. B., & Kang, E. H. (2022). Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: update with accumulated use of febuxostat. Seminars in Arthritis and Rheumatism, 56, 152080. https://doi.org/10.1016/j.semarthrit.2022.152080
[33] Timsans, J., Palom"aki, A., & Kauppi, M. (2024). Gout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications. Journal of Clinical Medicine, 13(24), 7616. https://doi.org/10.3390/jcm13247616
[34] van Durme, C. M. P. G., Wechalekar, M. D., Landewé, R. B. M., Pardo Pardo, J., Cyril, S., van der Heijde, D., & Buchbinder, R. (2021). Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database of Systematic Reviews, 12, CD010120. https://doi.org/10.1002/14651858.CD010120.pub3
[35] Victoria, A. Z., Riani, S., & Dahliyanti, N. D. (2024). Cadre Empowerment through "SEMUR Production" (Gout Education Program) in Improving Self-Management and Quality of Life of Gout Arthritis Sufferers. Journal of Community Service (JPKM) - Aphelion, 4 (September), 171–178. https://jurnal.globalhealthsciencegroup.com/index.php/JPM/article/view/2494
[36] Xie, H., Hu, N., Pan, T., & Wang, D.-C. (2023). Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. Rheumatology and Therapy. https://doi.org/10.1007/s40744-023-00649-1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indah Wahyu Setianingsih, Endang Setyowati, Intan Adevia Rosnarita
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
